CIC
GLUE icon

Cornercap Investment Counsel’s Monte Rosa Therapeutics GLUE Stock Holding History

Cornercap Investment Counsel’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,236
Closed -$102K – 499
2024
Q3 		$102K Sell
19,236
-22,681
-54% -$114K 0.03% 490
2024
Q2 		$157K Sell
41,917
-476
-1% -$2.43K 0.03% 553
2024
Q1 		$299K Buy
42,393
+14,549
+52% +$86.3K 0.05% 518
2023
Q4 		$157K Hold
27,844
– – 0.03% 544
2023
Q3 		$133K Sell
27,844
-348
-1% -$2.24K 0.02% 523
2023
Q2 		$193K Hold
28,192
– – 0.03% 518
2023
Q1 		$220K Hold
28,192
– – 0.04% 492
2022
Q4 		$215K Hold
28,192
– – 0.04% 511
2022
Q3 		$230K Buy
+28,192
New +$259K 0.04% 475

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cornercap Investment Counsel's GLUE Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Monte Rosa Therapeutics (GLUE) in Q4 2024, closing a stake of 19,236 shares — an estimated $102K sold.

Cornercap Investment Counsel first reported a position in GLUE in Q3 2022 and held it in 9 quarters. The position peaked at $299K in Q1 2024. 104 funds tracked by Wall St. Rank hold GLUE as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining Monte Rosa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 19,236 Monte Rosa Therapeutics shares in Q4 2024, an estimated $102K.
  • Cornercap Investment Counsel first reported a position in Monte Rosa Therapeutics in Q3 2022 and held it in 9 quarters.
  • Cornercap Investment Counsel's Monte Rosa Therapeutics position peaked at $299K in Q1 2024.
  • 104 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.